Importantly, based on our mechanistic biomarkers HIF1α and Gal3, we predicted that pancreatic cancers are particularly well amenable to Hsp90 inhibitor treatment, as both of these biomarkers are highly expressed in that cancer type [15]. Here, HIF1A is linked to pancreatic neoplasm.